At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
Ischaemic heart disease was the principal cause of death in Malaysia in 2016, and ST-segment elevation myocardial infarction (STEMI) is noted as the deadliest clinical presentation of Acute Coronary Syndrome. At the National Heart Association of Malaysia’s 2018 Annual Scientific Meeting, Professor Dr Wan Azman Wan Ahmad shared his insights into the management of STEMI in Malaysia, highlighting the implications of the recent TREAT trial.
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
In this issue of MIMS Cardiology Supplement, we bring you clinical updates related to combating hypercholesterolaemia, highlighting the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering low-density lipoprotein-cholesterol levels.
At a cardiology conference held in Hilton Kuala Lumpur, senior consultant cardiologist Dato’ Sri Dr Azhari Rosman spoke on the importance of non–high-density lipoprotein cholesterol (non–HDL-C) and combination therapy as a novel approach in the management of atherogenic dyslipidemia (AD).
Several high-density lipoprotein (HDL) functionality parameters, which are linked to HDL roles on cholesterol metabolism, endothelial protection and antioxidant/anti-inflammatory defence, contribute to an increased risk of incident acute coronary syndromes and its manifestations in individuals at high risk of cardiovascular disease, a study reports.
A wearable arrhythmia detection device, the AliveCor KardiaBand (KB), demonstrates moderate accuracy for diagnosing atrial fibrillation (AF) in comparison with a 12-lead electrocardiogram (ECG), as shown in a recent study. However, combining the automated device diagnosis with the electrophysiologists (EP) interpretation of unclassified readings improves overall accuracy.